Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Dec;85(24):9699-703.
doi: 10.1073/pnas.85.24.9699.

Role of interleukin 1 in the activation of T lymphocytes

Affiliations

Role of interleukin 1 in the activation of T lymphocytes

A H Lichtman et al. Proc Natl Acad Sci U S A. 1988 Dec.

Abstract

The activation of T lymphocytes requires their stimulation via clonotypic antigen receptors as well as nonantigen-specific costimulators, the best defined of which is the cytokine interleukin 1 (IL-1). Recent studies have shown that murine CD4+ helper T lymphocytes consist of two nonoverlapping subsets that selectively utilize interleukin 2 (IL-2) or interleukin 4 as their autocrine growth factors and are called Th1 and Th2 cells, respectively. We now show that IL-1 functions as a costimulator for the proliferation of Th2 but not of Th1 clones and only Th2 cells express high-affinity receptors for IL-1. Secretion of autocrine growth-promoting lymphokines by Th1 and Th2 cells occurs after stimulation via the antigen receptor-CD3 complex and is neither dependent on nor affected by IL-1. These findings suggest that the activation of T lymphocytes can be divided into two stages, lymphokine secretion and proliferation, and only proliferation requires costimulators such as IL-1. Moreover, the prevailing view that IL-1 functions as a costimulator by inducing secretion of IL-2 or expression of IL-2 receptors may not be generally applicable, because IL-2-producing Th1 clones do not express receptors for IL-1 and are insensitive to this cytokine.

PubMed Disclaimer

References

    1. J Exp Med. 1972 Jul 1;136(1):143-55 - PubMed
    1. J Clin Invest. 1988 Aug;82(2):420-6 - PubMed
    1. J Immunol. 1984 Sep;133(3):1339-45 - PubMed
    1. J Immunol. 1985 Mar;134(3):1682-9 - PubMed
    1. J Immunol. 1985 Oct;135(4):2249-55 - PubMed

Publication types